{
    "clinical_study": {
        "@rank": "69027", 
        "brief_summary": {
            "textblock": "To determine the appropriate duration of amphotericin B therapy for Candida esophagitis. To\n      compare the effectiveness of two different amphotericin B doses in the treatment of\n      biopsy-proven Candida esophagitis. To determine if low-dose amphotericin B is less toxic\n      than standard dose therapy during a limited treatment period. To evaluate pharmacokinetic\n      and pharmacodynamic parameters of the two different dosing regimens."
        }, 
        "brief_title": "Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients", 
        "condition": [
            "Candidiasis, Esophageal", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Candidiasis", 
                "Esophagitis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with histological or clinical (skin rash, cotton wool exudates, Candida\n        endophthalmitis, etc.) evidence of disseminated candidiasis are excluded.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Systemic administration of amphotericin B for a proven or suspected systemic fungal\n             infection.\n\n        Patients with the following are excluded:\n\n          -  Documented Candida fungemia.\n\n          -  Histological or clinical (skin rash, cotton wool exudates, Candida endophthalmitis,\n             etc.) evidence of disseminated candidiasis.\n\n          -  Systemic administration of amphotericin B for a proven or suspected systemic fungal\n             infection.\n\n          -  Patient refusal to enter study.\n\n        Patient must be an immunosuppressed host, with biopsy-proven Candida esophagitis.\n\n          -  Patients with polymicrobial esophagitis will be included as long as Candida\n             esophagitis is documented by esophageal biopsy.\n\n          -  Informed consent must be signed and obtained."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "16 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002041", 
            "org_study_id": "001A", 
            "secondary_id": "875-10"
        }, 
        "intervention": {
            "intervention_name": "Amphotericin B", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Amphotericin B", 
                "Liposomal amphotericin B"
            ]
        }, 
        "keyword": [
            "AIDS-Related Opportunistic Infections", 
            "Esophagitis", 
            "Acquired Immunodeficiency Syndrome", 
            "Amphotericin B", 
            "Candidiasis, Oral"
        ], 
        "lastchanged_date": "October 1, 2007", 
        "link": [
            {
                "description": "BMS Clinical Trials Disclosure", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Princeton", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "085434000"
                }, 
                "name": "Bristol - Myers Squibb Co"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients", 
        "overall_official": {
            "affiliation": ".", 
            "last_name": ". .", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002041"
        }, 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2007"
    }, 
    "geocoordinates": {
        "Bristol - Myers Squibb Co": "40.366 -74.679"
    }
}